Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

OncoImmunology

Volumn 5, Issue 4, 2016, Pages

  Besse, Benjamin ^a,b   Charrier, Mélinda ^a,b,c,d   Lapierre, Valérie ^a   Dansin, Eric ^e   Lantz, Olivier ^d,f,g   Planchard, David ^a   Le Chevalier, Thierry ^a   Livartoski, Alain ^f   Barlesi, Fabrice ^h   Laplanche, Agnès ^a   Ploix, Stéphanie ^d   Vimond, Nadège ^c,d   Peguillet, Isabelle ^d,f,g   Théry, Clotilde ^d,g   Lacroix, Ludovic ^a,c   Zoernig, Inka ⁱ   Dhodapkar, Kavita ^j,k   Dhodapkar, Madhav ^j,k   Viaud, Sophie ^a,b,l   Soria, Jean Charles ^a,b,c   Reiners, Katrin S ^m   Pogge von Strandmann, Elke ^m   Vély, Frédéric ^c,n,o   Rusakiewicz, Sylvie ^a,d,l   Eggermont, Alexander ^a,b,l   Pitt, Jonathan M ^a,b,l   Zitvogel, Laurence ^a,b,d,l   Chaput, Nathalie ^a,c,d   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

^d Centre d'Investigation Clinique Biothérapie CICBT 507 Gustave Roussy   (France)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f INSTITUT CURIE   (France)

^g PSL RESEARCH UNIVERSITY   (France)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k YALE CANCER CENTER   (United States)

^l University Paris XI   (France)

^m UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁿ CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^o HÔPITAL DE LA CONCEPTION   (France)

more..

Author keywords

cancer vaccine; exosomes; immunotherapy; NK cell; NSCLC; phase II trial

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GAMMA INTERFERON DENDRITIC CELL DERIVED EXOSOME VACCINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15 RECEPTOR ALPHA; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; TETRASPANIN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGENICITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN CELL; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR IMMUNITY; UPREGULATION;

EID: 84962844515     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1071008     Document Type: Article

References (41)

1. D.S.Chen, I.Mellman. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
2. G.Lizee, W.W.Overwijk, L.Radvanyi, J.Gao, P.Sharma, P.Hwu. Harnessing the power of the immune system to target cancer. Annu Rev Med 2013; 64:71-90; PMID:23092383; http://dx.doi.org/10.1146/annurev-med-112311-083918
3. P.W.Kantoff, C.S.Higano, N.D.Shore, E.R.Berger, E.J.Small, D.F.Penson, C.H.Redfern, A.C.Ferrari, R.Dreicer, R.B.Sims et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
4. J.M.Pitt, M.Charrier, S.Viaud, F.Andre, B.Besse, N.Chaput, L.Zitvogel. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J Immunol 2014; 193:1006-11; PMID:25049431; http://dx.doi.org/10.4049/jimmunol.1400703
5. P.D.Robbins, A.E.Morelli. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol 2014; 14:195-208; PMID:24566916; http://dx.doi.org/10.1038/nri3622
6. S.Viaud, M.Terme, C.Flament, J.Taieb, F.Andre, S.Novault, B.Escudier, C.Robert, S.Caillat-Zucman, T.Tursz et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PloS One 2009; 4:e4942; PMID:19319200; http://dx.doi.org/10.1371/journal.pone.0004942
7. H.G.Lamparski, A.Metha-Damani, J.Y.Yao, S.Patel, D.H.Hsu, C.Ruegg, J.B.Le Pecq. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002; 270:211-26; PMID:12379326; http://dx.doi.org/10.1016/S0022-1759(02)00330-7
8. S.Viaud, C.Thery, S.Ploix, T.Tursz, V.Lapierre, O.Lantz, L.Zitvogel, N.Chaput. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res 2010; 70:1281-5; PMID:20145139; http://dx.doi.org/10.1158/0008-5472.CAN-09-3276
9. B.Escudier, T.Dorval, N.Chaput, F.Andre, M.P.Caby, S.Novault, C.Flament, C.Leboulaire, C.Borg, S.Amigorena et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Trans Med 2005; 3:10; PMID:15740633; http://dx.doi.org/10.1186/1479-5876-3-10
10. M.A.Morse, J.Garst, T.Osada, S.Khan, A.Hobeika, T.M.Clay, N.Valente, R.Shreeniwas, M.A.Sutton, A.Delcayre et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Trans Med 2005; 3:9; PMID:15723705; http://dx.doi.org/10.1186/1479-5876-3-9
11. J.P.Pignon, H.Tribodet, G.V.Scagliotti, J.Y.Douillard, F.A.Shepherd, R.J.Stephens, A.Dunant, V.Torri, R.Rosell, L.Seymour et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552-9; PMID:18506026; http://dx.doi.org/10.1200/JCO.2007.13.9030
12. V.Polo, B.Besse. Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? Ann Oncol 2014; 25:1283-93; PMID:24351398; http://dx.doi.org/10.1093/annonc/mdt529
13. T.J.Lynch, I.Bondarenko, A.Luft, P.Serwatowski, F.Barlesi, R.Chacko, M.Sebastian, J.Neal, H.Lu, J.M.Cuillerot et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30:2046-54; PMID:22547592; http://dx.doi.org/10.1200/JCO.2011.38.4032
14. E.Segura, C.Nicco, B.Lombard, P.Veron, G.Raposo, F.Batteux, S.Amigorena, C.Thery. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 2005; 106:216-23; PMID:15790784; http://dx.doi.org/10.1182/blood-2005-01-0220
15. S.Utsugi-Kobukai, H.Fujimaki, C.Hotta, M.Nakazawa, M.Minami. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol Lett 2003; 89:125-31; PMID:14556969; http://dx.doi.org/10.1016/S0165-2478(03)00128-7
16. S.Viaud, S.Ploix, V.Lapierre, C.Thery, P.H.Commere, D.Tramalloni, K.Gorrichon, P.Virault-Rocroy, T.Tursz, O.Lantz et al. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-gamma. J Immunother 2011; 34:65-75; PMID:21150714; http://dx.doi.org/10.1097/CJI.0b013e3181fe535b
17. E.Segura, S.Amigorena, C.Thery. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells, Mol Dis 2005; 35:89-93; PMID:15990342; http://dx.doi.org/10.1016/j.bcmd.2005.05.003
18. K.M.Dhodapkar, S.N.Gettinger, R.Das, H.Zebroski, M.V.Dhodapkar. SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. Oncoimmunology 2013; 2:e25205; PMID:24073380; http://dx.doi.org/10.4161/onci.25205
19. V.Steimle, C.A.Siegrist, A.Mottet, B.Lisowska-Grospierre, B.Mach. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265:106-9; PMID:8016643; http://dx.doi.org/10.1126/science.8016643
20. N.Kamper, S.Franken, S.Temme, S.Koch, T.Bieber, N.Koch. Gamma-Interferon-regulated chaperone governs human lymphocyte antigen class II expression. FASEB J: Off Pub Federat Am Soc Exp Biol 2012; 26:104-16; PMID:21940994; http://dx.doi.org/10.1096/fj.11-189670
21. R.K.Pai, D.Askew, W.H.Boom, C.V.Harding. Regulation of class II MHC expression in APCs: roles of types I, III, and IV class II transactivator. J Immunol 2002; 169:1326-33; PMID:12133955; http://dx.doi.org/10.4049/jimmunol.169.3.1326
22. E.Pogge von Strandmann, V.R.Simhadri, B.von Tresckow, S.Sasse, K.S.Reiners, H.P.Hansen, A.Rothe, B.Boll, V.L.Simhadri, P.Borchmann et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007; 27:965-74; PMID:18055229; http://dx.doi.org/10.1016/j.immuni.2007.10.010
23. J.Matta, M.Baratin, L.Chiche, J.M.Forel, C.Cognet, G.Thomas, C.Farnarier, C.Piperoglou, L.Papazian, D.Chaussabel et al. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood; 2013; 122:394-404; PMID:23687088; http://dx.doi.org/10.1182/blood-2013-01-481705
24. M.Semeraro, S.Rusakiewicz, V.Minard-Colin, N.F.Delahaye, D.P.Enot, F.Vely, A.Marabelle, B.Papoular, C.Piperoglou, M.Ponzoni, et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med 2015; 7:283ra55; PMID:25877893; http://dx.doi.org/10.1126/scitranslmed.aaa2327; in press
25. S.Platonova, J.Cherfils-Vicini, D.Damotte, L.Crozet, V.Vieillard, P.Validire, P.Andre, M.C.Dieu-Nosjean, M.Alifano, J.F.Regnard et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011; 71:5412-22; PMID:21708957; http://dx.doi.org/10.1158/0008-5472.CAN-10-4179
26. K.Al-Shibli, S.Al-Saad, T.Donnem, M.Persson, R.M.Bremnes, L.T.Busund. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 2009; 55:301-12; PMID:19723145; http://dx.doi.org/10.1111/j.1365-2559.2009.03379.x
27. I.Takanami, K.Takeuchi, M.Giga. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Sur 2001; 121:1058-63; PMID:11385371; http://dx.doi.org/10.1067/mtc.2001.113026
28. K.S.Reiners, J.Kessler, M.Sauer, A.Rothe, H.P.Hansen, U.Reusch, C.Hucke, U.Kohl, H.Durkop, A.Engert et al. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther: J Am Soc Gene Ther 2013; 21:895-903; PMID:23459515; http://dx.doi.org/10.1038/mt.2013.14
29. K.S.Reiners, D.Topolar, A.Henke, V.R.Simhadri, J.Kessler, M.Sauer, M.Bessler, H.P.Hansen, S.Tawadros, M.Herling et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 2013; 121:3658-65; PMID:23509156; http://dx.doi.org/10.1182/blood-2013-01-476606
30. J.Binici, J.Koch. BAG-6, a jack of all trades in health and disease. Cell Mol Life Sci: CMLS 2014; 71:1829-37; PMID:24305946; http://dx.doi.org/10.1007/s00018-013-1522-y
31. A.Corduan, S.Lecomte, C.Martin, D.Michel, F.Desmots. Sequential interplay between BAG6 and HSP70 upon heat shock. Cell Mol Life Sci: CMLS 2009; 66:1998-2004; PMID:19357808; http://dx.doi.org/10.1007/s00018-009-9198-z
32. K.Thress, J.Song, R.I.Morimoto, S.Kornbluth. Reversible inhibition of Hsp70 chaperone function by Scythe and Reaper. EMBO J 2001; 20:1033-41; PMID:11230127; http://dx.doi.org/10.1093/emboj/20.5.1033
33. C.Massa, C.Melani, M.P.Colombo. Chaperon and adjuvant activity of hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. Cancer Res 2005; 65:7942-9; PMID:16140966; http://dx.doi.org/10.1158/0008-5472.CAN-05-0377
34. R.Gastpar, M.Gehrmann, M.A.Bausero, A.Asea, C.Gross, J.A.Schroeder, G.Multhoff. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res 2005; 65:5238-47; PMID:15958569; http://dx.doi.org/10.1158/0008-5472.CAN-04-3804
35. V.R.Simhadri, K.S.Reiners, H.P.Hansen, D.Topolar, V.L.Simhadri, K.Nohroudi, T.A.Kufer, A.Engert, E.Pogge von Strandmann. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PloS One 2008; 3:e3377; PMID:18852879; http://dx.doi.org/10.1371/journal.pone.0003377
36. C.Gross, I.G.Schmidt-Wolf, S.Nagaraj, R.Gastpar, J.Ellwart, L.A.Kunz-Schughart, G.Multhoff. Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. Cell Stress Chaperon 2003; 8:348-60; PMID:15115287; http://dx.doi.org/10.1379/1466-1268(2003)008%3c0348:HSPRIA%3e2.0.CO;2
37. C.Gross, D.Hansch, R.Gastpar, G.Multhoff. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol Chem 2003; 384:267-79; PMID:12675520; http://dx.doi.org/10.1515/BC.2003.030
38. R.N.Germain, M.Bajenoff, F.Castellino, M.Chieppa, J.G.Egen, A.Y.Huang, M.Ishii, L.Y.Koo, H.Qi. Making friends in out-of-the-way places: how cells of the immune system get together and how they conduct their business as revealed by intravital imaging. Immunol Rev 2008; 221:163-81; PMID:18275481; http://dx.doi.org/10.1111/j.1600-065X.2008.00591.x
39. N.F.Delahaye, S.Rusakiewicz, I.Martins, C.Menard, S.Roux, L.Lyonnet, P.Paul, M.Sarabi, N.Chaput, M.Semeraro et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-7; PMID:21552268; http://dx.doi.org/10.1038/nm.2366
40. I.Zornig, N.Halama, J.Lorenzo Bermejo, C.Ziegelmeier, E.Dickes, A.Migdoll, I.Kaiser, T.Waterboer, M.Pawlita, N.Grabe et al. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients. Int J Cancer 2015; 136:138-51; PMID:24839182; http://dx.doi.org/10.1002/ijc.28980
41. R.Spisek, A.Kukreja, L.C.Chen, P.Matthews, A.Mazumder, D.Vesole, S.Jagannath, H.A.Zebroski, A.J.Simpson, G.Ritter et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007; 204:831-40; PMID:17389240; http://dx.doi.org/10.1084/jem.20062387